Galanis, Evanthia http://orcid.org/0000-0001-8014-786X
Dooley, Katharine E. http://orcid.org/0000-0003-4565-5767
Keith Anderson, S. http://orcid.org/0000-0003-1542-9726
Kurokawa, Cheyne B.
Carrero, Xiomara W.
Uhm, Joon H.
Federspiel, Mark J.
Leontovich, Alexey A.
Aderca, Ileana
Viker, Kimberly B.
Hammack, Julie E.
Marks, Randolph S.
Robinson, Steven I.
Johnson, Derek R.
Kaufmann, Timothy J.
Buckner, Jan C.
Lachance, Daniel H.
Burns, Terry C. http://orcid.org/0000-0001-7633-3045
Giannini, Caterina http://orcid.org/0000-0003-2757-6782
Raghunathan, Aditya
Iankov, Ianko D.
Parney, Ian F.
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01 CA258239, P50 CA108961, R21 CA123839)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
The Ben & Catherine Ivy Foundation
Article History
Received: 25 January 2023
Accepted: 31 October 2023
First Online: 12 January 2024
Competing interests
: The authors declare no competing interests or other interests that might be perceived to influence the interpretation of the article. Outside of this submission, EG has received honoraria for advisory board participation from Kiyatec, Inc. (personal compensation) and Karyopharm Therapeutics, Inc. for Data Safety and Monitoring Board participation (compensation to the employer). Her institution has received grant funding from Servier Pharmaceuticals LLC (formerly Agios Pharmaceuticals, Inc.), Celgene, MedImmune, Inc. and Tracon Pharmaceuticals. The remaining authors declare no competing interests.